Clinical Takeaway
A randomized controlled trial tested the Minder mobile app, co-designed with university students, to address mental health and substance use concerns during the high-risk transition into university life. Digital tools like this are being studied because they can reach large numbers of students who may not seek traditional care. Results from this trial offer evidence-based guidance on whether app-based interventions can meaningfully improve outcomes in this population.
#4 Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial.
Citation: Vereschagin Melissa et al.. Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial.. Journal of medical Internet research. 2024. PMID: 38536225.
Design: 5 Journal: 0 N: 3 Recency: 1 Pop: 2 Human: 1 Risk: 0
This randomized controlled trial provides evidence on whether scalable digital interventions can effectively address the concurrent mental health and substance use disorders that commonly emerge during the critical university transition period. The codevelopment methodology with students ensures the app’s design reflects end-user needs, potentially improving real-world adoption and clinical utility compared to standard interventions. Establishing efficacy of such mobile platforms is clinically significant given their potential to extend evidence-based care to large student populations with limited access to traditional mental health services.
Abstract: BACKGROUND: University attendance represents a transition period for students that often coincides with the emergence of mental health and substance use challenges. Digital interventions have been identified as a promising means of supporting students due to their scalability, adaptability, and acceptability. Minder is a mental health and substance use mobile app that was codeveloped with university students. OBJECTIVE: This study aims to examine the effectiveness of the Minder mobile app in improving mental health and substance use outcomes in a general population of university students. METHODS: A 2-arm, parallel-assignment, single-blinded, 30-day randomized controlled trial was used to evaluate Minder using intention-to-treat analysis. In total, 1489 participants were recruited and randomly assigned to the intervention (n=743, 49.9%) or waitlist control (n=746, 50.1%) condition. The Minder app delivers evidence-based content through an automated chatbot and connects participants with services and university social groups. Participants are also assigned a trained peer coach to support them. The primary outcomes were measured through in-app self-assessments and included changes in general anxiety symptomology, depressive symptomology, and alcohol consumption risk measured using the 7-item General Anxiety Disorder scale, 9-item Patient Health Questionnaire, and US Alcohol Use Disorders Identification Test-Consumption Scale, respectively, from baseline to 30-day follow-up. Secondary outcomes included measures related to changes in the frequency of substance use (cannabis, alcohol, opioids, and nonmedical stimulants) and mental well-being. Generalized linear mixed-effects models were used to examine each outcome. RESULTS: In total, 79.3% (589/743) of participants in the intervention group and 83% (619/746) of participants in the control group completed the follow-up survey. The intervention group had significantly greater average reductions in anxiety symptoms measure
🧠 While this randomized controlled trial of the Minder app shows promise as a scalable digital intervention for university students navigating mental health and substance use challenges, clinicians should note that mobile app efficacy in controlled trials often differs substantially from real-world effectiveness, particularly regarding adherence and sustained engagement over time. The study’s reliance on self-reported outcomes and the homogeneity of university populations limits generalizability to diverse patient populations with more severe or complex psychiatric presentations, and we lack clarity on whether benefits persist beyond the intervention period or translate to meaningful reductions in cannabis use specifically. Additionally, the codevelopment with students enhances acceptability but raises questions about whether the app adequately addresses the motivational ambivalence and neurobiological factors that underlie problematic substance use in younger adults. Rather than viewing this as a standalone treatment, clinicians might consider recommending such apps as an adjunctive tool within a broader care model that includes regular clinical contact, especially for students with active substance use or moderate to severe psychiatric symptoms.